Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Non-Current Assets (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Non-Current Assets for 15 consecutive years, with $33.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Non-Current Assets fell 2.4% to $33.0 million in Q4 2025 year-over-year; TTM through Oct 2025 was $33.0 million, a 2.4% decrease, with the full-year FY2025 number at $32.8 million, up 246.5% from a year prior.
  • Non-Current Assets was $33.0 million for Q4 2025 at PharmaCyte Biotech, up from $26.0 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $37.3 million in Q3 2024 to a low of $5.1 million in Q1 2021.
  • A 5-year average of $13.5 million and a median of $5.1 million in 2021 define the central range for Non-Current Assets.
  • Peak YoY movement for Non-Current Assets: surged 627.57% in 2024, then crashed 30.32% in 2025.
  • PharmaCyte Biotech's Non-Current Assets stood at $5.1 million in 2021, then changed by 0.0% to $5.1 million in 2022, then changed by 0.0% to $5.1 million in 2023, then soared by 558.28% to $33.8 million in 2024, then dropped by 2.4% to $33.0 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Non-Current Assets are $33.0 million (Q4 2025), $26.0 million (Q3 2025), and $32.8 million (Q2 2025).